77477_INDEX.

qxd 11/7/06 6:38 PM Page 535

© Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION

Index
Note: Trade drug names are cyclophosphamide, ondansetron, 521–523
initially capitalized. 98–102 palonosetron, 524–525
dacarbazine, 109–111 prochlorperazine,
Abraxane (albumin-bound ifosfamide, 222–225 526–528
paclitaxel), 15–18 lomustine, 249–257 regimens for, 529–531
Actinomycin-D mechlorethamine, antiestrogens
(dactinomycin-D), 252–254 tamoxifen, 332–335
112–114 melphalan, 258–260 toremifene, 352–354
acute lymphocytic procarbazine, 261–314 Anti-HER-2-antibody
leukemia, 430–434 streptozocin, 325–327 (trastuzumab), 359–361
acute myelogenous temozolomide, 336–338 antimetabolites
leukemia, 434–435 thiotepa, 346–348 capecitabine, 65–70
adjuvant therapy All-trans-retinoic acid cladribine, 91–94
brain cancer, 401–402 (tretinoin), 362–365 clofarabine, 95–97
breast cancer, 403–405 Aloxi (palonosetron), cytarabine, 105–108
colorectal cancer, 524–525 floxuridine, 179–182
414–415 altretamine (Hexalen; fludarabine, 183–186
esophageal cancer, Hexamethylmelamine; 5–fluorouracil, 187–192
422–423 HMM), 26–28 gemcitabine, 201–204
gastric cancer, 423–426 Amethopterin hydroxyurea, 211–213
goal of, 2–3 (methotrexate), mercaptopurine,
melanoma, malignant, 268–274 261–264
4–53 amifostine (Ethyol; methotrexate, 268–274
non small cell lung WR2721), 29–31 pemetrexed, 304–307
cancer, 438–439 aminoglutethimide pentostatin, 308–310
rationale for, 4–5 (Cytadren; Epiten), thioguanine, 343–345
testicular cancer, 467 32–34 antimicrotubule agents
adrenolytic agent, 279–281 amputees, body surface albumin-bound
adrenosteroid inhibitor area of adults, 382 paclitaxel, 15–18
(aminoglutethimide), anal cancer, 398–399 docetaxel, 139–143
32–34 anastrozole (Arimidex), estramustine, 163–165
Adriamycin (doxorubicin), 35–37 paclitaxel, 293–297
144–148 antiandrogens vinblastine, 366–369
advanced disease bicalutamide, 53–54 vincristine, 370–374
brain cancer, 402 flutamide, 193–194 vinorelbine, 375–378
pancreas cancer, 460 nilutamide, 286–288 antitumor antibiotics
testicular cancer, antiangiogenic agent bleomycin, 55–58
467–468 (thalidomide), dactinomycin-D,
albumin-bound paclitaxel 339–342 112–114
(Abraxane), 15–18 Anti-EGFR-antibody daunorubicin, 122–125
aldesleukin (Interleukin-2; (cetuximab), 79–81 daunorubicin liposome,
IL-2: Proleukin), 19–21 antiemetic agents, 499–534 126–129
alemtuzumab (Campath), aprepitant, 500–501 doxorubicin, 144–148
22–25 dexamethasone, doxorubicin liposome,
Alimta (pemetrexed), 502–504 149–152
304–307 diphenhydramine, epirubicin, 153–156
Alkeran (melphalan), 505–506 idarubicin, 218–221
258–260 dolasetron, 507–509 mitomycin-C, 275–278
alkylating agents dronabinol, 510–511 mitoxantrone, 282–285
altretamine, 26–28 granisetron, 512–514 Anti-VEGF-antibody
busulfan, 62–64 lorazepam, 515–517 (bevacizumab), 46–49
carmustine, 75–78 metoclopramide, Anzemet (dolasetron),
chlorambucil, 82–84 518–520 507–509

Index 535
77477_INDEX.qxd 11/7/06 6:38 PM Page 536

© Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION

aprepitant (Emend), sargramostim, 319–321 chemoradiation therapy

500–501 tositumomab, 355–358 anal cancer, 398–399
Ara-C (cytarabine), 103–108 trastuzumab, 359–361 bladder cancer,
Aranesp (darbopoetin alfa), Bischloronitrosourea 399–401
115–118 (carmustine), 75–78 brain cancer, 401–402
area under the curve Bischloronitrosourea esophageal cancer,
(AUC), 381 (lomustine), 249–251 422–423
Arimidex (anastrozole), bladder cancer, 399–401 chemotherapy
35–37 bleomycin (Blenoxane), See also under specific
Aromasin (exemestane), 55–58 malignancies.
174–175 body surface area (BSA), alternating cycles of,
Aromatase inhibitor, 381–382 8–9
243–245 bortezomib (Velcade), combination,
Arsenic trioxide (As2O3; 59–61 principles of, 6–10
Trisenox), 38–41 brain cancer, 401–402 development of, 1
asparaginase (Elspar; breast cancer, 403–410 dose intensity concept,
L-Asparaginase), 42–45 BSA (body surface area), 10–12
Ativan (lorazepam), 381–382 duration of, 9
362–365 Burkitt’s lymphoma, mechanisms of action, 1
ATRA (tretinoin), 362–365 451–452 principles of, 1–12
AUC (area under the curve), Busulfan (Busulfex; regimens, 397–464
381 Myleran), 62–64 role in cancer
Avastin (bevacizumab), treatment, 2–3
46–49 Campath (alemtuzumab), single-agent regimens.
22–25 See single-agent
BCNU (carmustine), 75–78 Camptosar (irinotecan), regimens.
Benadryl (diphenhy- 235–239 chemotherapy and
dramine), 505–506 cancer, See also specific differentiating agent
bevacizumab (Avastin; cancers (arsenic trioxide), 38–41
Anti-VEGF-antibody), of unknown primary, chemotherapy drugs
46–49 410–411 albumin-bound
bexarotene (Targretin), capecitabine (Xeloda), paclitaxel, 15–18
50–52 65–70 altretamine, 26–28
Bexxar (tositumomab), carboplatin (Paraplatin; arsenic trioxide, 38–41
355–358 CBDCA), 71–74 asparaginase, 42–45
bicalutamide (Casodex), carcinoid tumors, 411–412 bleomycin, 55–58
53–54 carmustine (BCNU; bortezomib, 59–61
BiCNU (carmustine), 75–78 Bischloronitrosourea; busulfan, 62–64
biliary tract cancer, 399 BiCNU), 75–78 capecitabine, 65–70
biologic response Casodex (bicalutamide), carboplatin, 71–74
modifier agents 53–54 carmustine, 75–78
aldesleukin, 19–21 CBDCA (carboplatin), chlorambucil, 82–84
alemtuzumab, 22–25 71–74 cisplatin, 85–90
bevacizumab, 46–49 CCNU (lomustine), cladribine, 91–94
cetuximab, 79–81 249–251 clofarabine, 95–97
darbopoetin alfa, 115–18 2-CdA (cladribine), 91–94 cyclophosphamide,
denileukin diftitox, CDDP (cisplatin), 83–90 98–102
133–135 Cerubinidine cytarabine, 103–108
erythropoietin, 160–162 (daunorubicin), 122–125 dacarbazine, 109–111
filgrastim, 176–178 cervical cancer, 412–413 dactinomycin-D,
gemtuzumab cetuximab (Erbitux; Anti- 112–114
ozogamicin, 205–208 EGFR antibody), 79–81 daunorubicin, 122–125
ibritumomab, 214–217 chemoprotective drugs daunorubicin liposome,
interferon-
, 231–234 amifostine, 29–31 126–129
pegfilgrastim, 301–303 dexrazoxane, 136–138 dialysis of, 391–393
rituximab, 315–318 mesna, 265–267 docetaxel, 139–143

536 Index
77477_INDEX.qxd 11/7/06 6:38 PM Page 537

© Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION

dosage. See drug chlorambucil (Leukeran), head and neck cancer,

dosage, 82–84 426–428
doxorubicin, 144–148 2-Chlorodeoxyadenosine Hodgkin’s disease,
doxorubicin liposome, (cladribine), 91–94 443–446
149–152 chronic lymphocytic Kaposi’s sarcoma,
emetogenic potential, leukemia, 435–437 429–430
531–534 chronic myelogenous limitations of, 11–12
epirubicin, 153–156 leukemia, 437–438 melanoma, malignant,
erlotinib, 157–159 cisplatin (Cis- 453–454
estramustine, 163–165 diamminedichloroplat- mesothelioma,
etoposide, 166–169 inum; CDDP; Platinol), malignant, 455
etoposide phosphate, 85–90 multiple myeloma,
170–173 cladribine (2- 456–457
evaluation of response, Chlorodeoxyadenosine; non-Hodgkin’s disease,
clinical endpoints for, 2-CdA; Leustatin), 446–453
3–5 91–94 non-small cell lung
floxuridine, 179–182 clofarabine (Clolar), 95–97 cancer, 438–439
fludarabine, 183–186 CMA-676 (gemtuzumab non-small cell lung
5–fluorouracil, 187–192 ozogamicin), 205–208 cancer metastatic
gefitinib, 198–200 CNS lymphoma, primary, disease, 439–441
gemcitabine, 201–204 452–453 ovarian cancer,
hydroxyurea, 211–213 Cockcrof t-Gault formula, epithelial 458–459
idarubicin, 218–221 380–381 ovarian cancer, germ
ifosfamide, 222–225 colony-stimulating growth cell, 460
imatinib, 226–230 factors pancreas cancer
irinotecan, 235–239 in combination metastatic disease, 460
local skin toxicities, chemotherapy, 7 primary CNS
393–395 darbopoetin alfa, lymphoma, 452
lomustine, 249–251 115–118 principles of, 6–10
mechlorethamine, erythropoietin, 160–162 prostate cancer,
252–254 filgrastim, 176–178 462–463
melphalan, 258–260 pegfilgrastim, 301–303 renal cell cancer, 465
mercaptopurine, sargramostim, 319–321 small cell lung cancer,
261–264 colorectal cancer, 414–420 442–443
methotrexate, 268–274 combination chemotherapy soft tissue sarcomas,
mitomycin-C, 275–278 anal cancer, 398–399 466
mitotane, 279–281 biliary tract cancer, 399 testicular cancer,
mitoxantrone, 282–285 bladder cancer, 399–401 467–468
oxalliplatin, 289–292 brain cancer, 401–402 thymoma, 468–469
paclitaxel, 293–297 breast cancer, 403–410 thyroid cancer, 469
pemetrexed, 304–307 Burkitt’s lymphoma, Compazine
pentostatin, 308–310 451–452 (prochlorperazine),
percentage of dosage cancer of unknown 526–528
based on hematologic primary, 410–411 complete response
parameters, 382 carcinoid tumors, rate, 3
procarbazine, 311–314 411–412 consolidation therapy
streptozocin, 325–327 cervical cancer, 412–413 acute lymphocytic
temozolomide, 336–338 chronic lymphocytic leukemia, 430–431
teratogenic potential, leukemia, 435–437 acute myelogenous
396 chronic myelogenous leukemia, 433
thioguanine, 343–345 leukemia, 437–438 Cosmegen (dactinomycin-D)
thiotepa, 346–348 colorectal cancer, 414 112–114
topotecan, 349–351 colorectal metastatic CPM (cyclophosphamide),
vinblastine, 366–369 disease, 415–419 98–102
vincristine, 370–374 endometrial cancer, CPT-11 (irinotecan),
vinorelbine, 375–378 420–421 235–239

Index 537
77477_INDEX.qxd 11/7/06 6:38 PM Page 538

© Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION

creatinine clearance, deter- 2’-Dexoycoformycin; Ellence (epirubicin),

mination of, 380–381 Nipent, dCF 153–156
cyclophosphamide (pentostatin), 308–310 Eloxatin (oxaliplatin),
(CTX; Cytoxan; CPM; dexrazoxane (Zinecard; 289–292
Neosar), 98–102 ICRF-187), 136–138 Elspar (asparaginase),
Cytadren (aminoglu- DHAD (mitoxantrone), 42–45
tethimide), 32–34 282–285 Emcyt (estramustine),
cytarabine (Cystosine DHAQ (mitoxantrone), 163–165
arabinoside; Ara-C; 282–285 Emend (aprepitant),
Cytosar U), 103–108 dialysis, of chemotherapy 500–501
cytokines. See also drugs, 391–393 emetogenic potential, of
colony-stimulating Diaminocyclohexane chemotherapy drugs,
growth factors platinum (oxaliplatin), 531–533
aldesleukin, 19–21 289–292 endometrial cancer,
darbopoetin alfa, DIC (dacarbazine), 109–111 420–422
115–118 differentiating agents enzyme (asparaginase),
erythropoietin, 160–162 arsenic trioxide, 38–41 42–45
filgrastim, 176–178 bexarotene, 50–52 4’ Epi-doxorubicin
pegfilgrastim, 301–303 tretinoin, 362–365 (epirubicin), 153–156
Cytosar U (cytarabine), diphenhydramine, 505–506 epipodophyllotoxins
103–108 diphenhydramine etoposide, 166–169
Cytosine arabinoside (Benadryl), 506 etoposide phosphate,
(cytarabine), 103–108 docetaxel (Taxotere), 170–173
Cytoxan (cyclophos- 139–143 epirubicin,
phamide), 98–102 dolasetron (Anzemet), (4’ Epidoxorubicin;
507–509 Ellence), 153–156
DABs (denileukin dosage, drug Epiten (aminoglu-
diftitox), 133–135 based on hepatic tethimide), 32–34
dacarbazine (DIC; function, 383–387 epithelial ovarian cancer,
DTIC-Dome; Imidazole based on renal 458–460
Carboxamide), 109–111 function, 387–391 Epogen (EPO; Epoietin
DACH-platinum determination of, alfa; erythropoietin),
(oxaliplatin), 289–292 380–381 160–162
dactinomycin-D dose intensity concept, Erbitux (cetuximab), 79–81
(Actinomycin-D; 10–12 erlotinib (Tarceva; OSI-774),
Cosmegen), 112–114 dose-dense delivery, of 157–159
darbopoetin alfa (Aranesp), chemotherapy, 11–12 erythropoietin
115–118 dose-response curves, 10–11 (Procrit; Epogen;
daunorubicin Doxil (doxorubicin EPO; Epoietin alfa),
(Daunomycin; liposome), 149–152 160–162
Cerubinidine; doxorubicin (Adriamycin; esophageal cancer, 422–423
Rubidomycin), 122–125 Hydroxydaunorubicin), estramustine (Estracyte;
daunorubicin liposome 144–148 Emcyt), 163–165
(DaunoXome), 126–129 doxorubicin liposome estrogen receptor antago-
dCF (pentostatin), (Doxil), 149–152 nist (fulvestrant),
308–310 dronabinol (Marinol), 195–197
Decadron (dexamethasone), 510–511 Ethyol (amifostine), 29–31
502–504 DTIC-Dome (dacarbazine), etoposide (VePesid;
delivery, of chemotherapy, 109–111 VP-16), 166–169
11–12 duration, of etoposide phosphate
4–Demethoxydaunorubicin chemotherapy, 9 (Etopophos), 170–173
(idarubicin), 218–221 Eulexin (flutamide),
denileukin diftitox ECOG Performance 193–194
(Ontak; DABs), 133–135 Scale, 380 Ewing’s sarcoma, 466
dexamethasone Efudex (5-fluorouracil), exemestane (Aromasin),
(Decadron), 502–504 187–192 174–175

538 Index
77477_INDEX.qxd 11/7/06 6:38 PM Page 539

© Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION

Fareston (toremifene), Granulocyte-macrophage IL-2 (aldesleukin), 19–21

352–354 colony-stimulating imatinib (ST1571; Gleevec),
Faslodex (fulvestrant), factor (sargramostim), 226–230
195–197 319–321 Imidazole carboxamide
Femara (letrozole), 243–245 (dacarbazine), 109–111
filgrastim (Neupogen; hairy cell leukemia, 438 Immunomodulatory
G-CSF), 176–178 head and neck cancer, agent, 339–342
floxuridine (5-Fluoro- 426–429 Immunotherapy
2-deoxyuridine; hepatocellular cancer, 429 aldesleukin, 19–21
FUDR), 179–182 Herceptin (trastuzumab), denileukin diftitox,
fludarabine (2-Fluoro- 359–361 133–135
ara-amp; Fludara), Hexalen interferon-
, 231–234
183–186 (Hexamethylmelamine; induction therapy,
5-Fluoro-2’-deoxyuridine HMM; altretamine), acute lymphocytic
(floxuridine), 179–182 26–28 leukemia, 430–434
5-fluorouracil Hodgkin’s disease, acute myelogenous
(5–FU; Efudex), 187–192 443–446 leukemia, 434
flutamide (Eulexin), hormonal agents partial response to, 3
193–194 aminoglutethimide, Interferon-
(IF-
;
5-FU (5-fluorouracil), 32–34 Interferon-
2a;
187–192 anastrozole, 35–37 Roferon interferon-

FUDR (floxuridine), bicalutamide, 53–54 2b; Intron A), 231–234
179–182 exemestane, 174–175 Interleukin-2; IL-2;
fulvestrant (Faslodex), flutamide, 193–194 Proleukin (aldesleukin),
195–197 fulvestrant, 195–197 19–21
goserelin, 209–210 Intron A (interferon-
),
gastric cancer, 423–426 letrozole, 243–245 231–234
gastrointestinal stromal leuprolide, 246–248 Iressa (gef itinib),
tumor (GIST), 426 megestrol acetate, 198–200
G-CSF (filgrastim), 176–178 255–257 irinotecan (Camptosar;
gefitinib (Iressa; ZD1839), nilutamide, 286–288 CPT-11), 235–239
198–200 tamoxifen, 332–335 Iron-chelating agent,
gemcitabine (Gemzar), toremifene, 352–354 136–138
201–204 Hycamtin (topotecan), irritants, chemotherapy
gemtuzumab ozogamicin 349–351 drug, 393–395
(Mylotarg; CMA-676), Hydrea (hydroxyurea), Isophosphamide
205–208 211–213 (ifosfamide), 222–225
Gemzar (gemcitabine), Hydroxydaunorubicin
201–204 (doxorubicin), 144–148 Kaposi’s, sarcoma,
germ cell ovarian hydroxyurea (Hydrea), 429–430
cancer, 460 211–213 Karnofsky Performance
GIST (gastrointestinal Scale, 380
stromal tumor), 426 ibritumomab (Zevalin; kinetics, of tumor cell
Gleevec (imatinib), IDEC-Y2B8), 214–217 growth, 5–6
226–230 ICRF-187 (dexrazoxane), Kytril (granisetron),
GM-CSF (sargramostim), 136–138 512–514
319–321 idarubicin (Idamycin;
Goldie-Coldman 4-Demethoxy- Larson regimen, 432
hypothesis, 8–9 daunorubicin), 218–221 L-Asparaginase
Gompertzian model of IDEC-Y2B8 (ibritumomab), (asparaginase), 42–45
tumor growth and 214–217 letrozole (Femara), 243–245
regression, 6 IF-
(interferon-
), leukemia, 430–438
goserelin (Zoladex), 231–234 acute lymphocytic,
209–210 ifosfarmide (Ifex; 430–434
granisetron (Kytril), Isophosphamide), acute myelogenous,
512–514 222–225 434–435

Index 539
77477_INDEX.qxd 11/7/06 6:38 PM Page 540

© Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION

chronic lymphocytic, mechlorethamine MTX (methotrexate),

435–437 (Mustargen; Nitrogen
chronic myelogenous, mustard), 252–254
437–438 megestrol acetate (Megace),
hairy cell, 438 255–257
murine, Kinetics of melanoma, malignant,
tumor cell growth, 5–6 453–455
Leukeran (chlorambucil), melphalan (Alkeran;
82–84 Phenylalanine mustard;
Leukine (sargramostim), L-PAM), 258–260
319–321 2-Mercaptoethanesulfonic
leuprolide (Lupron), acid (mesna), 265–267
246–248 mercaptopurine (6-MP;
Leustatin (cladribine), Purinethol), 261–264
91–94 mesna (Mesnex;
LHRH agonists 2-Mercaptoethane-
buserelin, 74–75 sulfonic acid), 265–267
goscrelin, 209–210 mesothelioma,
leuprolide, 246–248 malignant, 455
Linker regimen, 430–431 metastatic disease
L1210 murine model, 5 anal cancer, 398–399
lomustine (CCNU; breast cancer, 405–408
Bischloronitrosourea), colorectal cancer,
249–257 415–419
lorazepam (Ativan), 515–517 esophageal cancer, 423
L-PAM (melphalan), melanoma, malignant,
258–260 453–454
lung cancer, non-small cell lung
non-small cell, 438–442 cancer, 439–441
small cell, 442–443 pancreas cancer, 461
Lupron (leuprolide), methotrexate (MTX;
246–248 Amethopterin),
luteinizing hormone- 268–274
releasing hormone N-Methylhydrazine
agonists. See LHRH (procarbazine), 311–314
agonists metoclopramide (Reglan),
LY231514 (pemetrexed), 518–520
304–307 mitomycin-G (Mutamycin;
lymphoma, 443–453 Mitomycin), 275–278
Burkitt’s, 451–452 mitotane (o, p-DDD;
CNS, primary, 452–453 Lysodren), 279–281
Hodgkin’s, disease, mitoxantrone (Novantrone;
443–446 DHAD; DHAQ),
non-Hodgkin’s, 282–285
446–453 monoclonal antibodies
Lysodren (mitotane), alemtuzumab, 22–25
279–281 bevacizumab, 46–49
cetuximab, 79–81
Magrath protocol, 451 gemtuzumab
maintenance therapy, ozogamicin, 205–208
for acute lymphocytic ibritumomab, 214–217
leukemia, 431 rituximab, 315–318
Marinol (dronabinol), tositumomab, 355–358
510–511 trastuzumab, 359–361
Matulane (procarbazine), 6-MP (mercaptopurine),
311–314 261–264
268–274
multiple myeloma,
456–457
Mustargen
(mechlorethamine),
252–254
Mutamycin (mitomycin-G),
275–278
Myleran (busulfan),
62–64
Mylotarg (gemtuzumab
ozogamicin), 205–208
Natural product, arsenic
trioxide, 38–41
Navelbine (vinorelbine),
375–378
neoadjuvant therapy breast
cancer, 403
colorectal cancer, 414
rationale for, 2, 4
Neosar (cyclophosphamide),
98–102
Neulasta (pegfilgrastim),
301–303
Neupogen (filgrastim),
176–178
nilutamide (Nilandron),
286–288
Nipent (pentostatin),
308–310
Nitrogen mustard
(mechlorethamine),
252–254
Nolvadex (tamoxifen),
332–335
non-Hodgkin’s lymphoma,
446–453
non-small cell lung cancer,
438–442
nonsteroidal aromatasc
inhibitor, 35–37
Novantrone (mitoxantrone),
282–285
Oncovin (vincristine),
370–374
Ondansetron (Zofran),
521–523
Ontak (denileukin diftitox),
133–135
O, p-DDD (mitotane),
279–281
OSI-774 (erlotinib),
157–159

540 Index
77477_INDEX.qxd 11/7/06 6:38 PM Page 541

© Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION

ovarian cancer, 458–460 proteosome inhibitor colorectal cancer,

epithelial, 458–460 (bortezomib), 59–61 419–420
germ cell, 460 Purinethol (mercapto- endometrial cancer,
oxaliplatin purine), 261–264 421–422
(Diaminocyclohexane esophageal cancer, 423
platinum; DACH- radiation therapy, with gastric cancer, 425–426
platinum; Eloxatin), chemotherapy. See gastrointestinal stromal
289–292 chemoradiation therapy tumor, 426
Reglan (metoclopramide), hairy cell leukemia, 438
paclitaxel (Taxol), 293–297 518–520 head and neck cancer,
palonosetron (Aloxi), relapse-free survival, 3–4 428–429
524–525 renal cell cancer, 465 hepatocellular cancer,
L-PAM (melphalan), resistance to chemotherapy 429
258–260 Goldie-Coldman Kaposi’s sarcoma, 430
pancreas cancer, hypothesis, 8–9 melanoma, malignant,
460–462 spontaneous, 9 454–455
Paraplatin (carboplatin), retinoids metastatic breast
71–74 bexarotene, 50–52 cancer, 408–410
partial response, 3 tretinoin, 362–365 multiple myeloma, 457
pegfilgrastim (Neulasta; rituximab (Ritixan), 315–318 non-small cell lung
PEG-rHuG-CSF), Roferon interferon-
2b cancer metastatic
301–303 (interferon-
), 231–234 disease, 440–441
PEG-rHuG-CSF Rubidomycin ovarian cancer,
(pegfilgrastim), 301–303 (daunorubicin), epithelial, 459–460
pemetrexed (Alimta; 122–125 pancreas cancer
LY231514), 304–307 metastatic disease, 462
pentostatin (2- salvage therapy primary CNS
Dexoycoformycin; anal cancer, 399 lymphoma, 453
Nipent, dCF), 308–310 non-Hodgkin’s disease, prostate cancer,
performance scales, 380 450–451 463–465
Phenylalanine mustard testicular cancer, 468 renal cell cancer, 465
(melphalan), 258–260 sargramostim (Granulocyte small cell lung
Platinol (cisplatin), 85–90 macrophage cancer, 443
platinum analogs colony-stimulating soft tissue sarcomas,
carboplatin, 71–74 factor; GM-CSF; 466–467
cisplatin, 85–90 Leukine), 319–321 thyroid cancer, 469
Oxalliplatin, 289–292 sequential chemotherapy, vs small cell lung cancer,
pregnancy, use of chemo- combination 442–443
therapy drugs in, 396 chemotherapy, 12 soft tissue sarcomas,
primary CNS lymphoma, signal transduction 466–467
452–453 inhibitors ST1571 (imatinib),
primay induction erlotinib, 157–169 226–230
chemotherapy, 2 gefitinib, 198–200 Stanford regimen, 452
procarbazine (Matulane; imatinib, 226–230 steroidal aromatase
N-Methylhydrazine), single-agent regimens inactivator, 174–175
311–314 acute lymphocytic streptozocin (Streptozotocin;
prochlorperazine leukemia, 434 Zanosar), 325–327
(Compazine), 526–528 acute myelogenous sulfhydryl compound
Procrit (erythropoietin), leukemia, 435 (mesna), 265–267
160–162 bladder cancer, 401
progestational agent brain cancer, 402 tamoxifen (Nolvadex),
(megestrol acetate), breast cancer, 405 332–335
255–257 carcinoid tumors, 412 Tarceva (erlotinib),
Proleukin (aldesleukin), cervical cancer, 413 157–159
19–21 chronic lymphocytic Targretin (bexarotene),
prostate cancer, 462–465 leukemia, 436–437 50–52

Index 541
77477_INDEX.qxd 11/7/06 6:38 PM Page 542

© Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION

taxanes thyroid cancer, 469 VePesid (etoposide),

albumin-bound topoisomerase I inhibitors 166–169
paclitaxel, 15–18 irinsotecan, 235–239 Vesanoid (tretinoin),
docetaxel, 139–143 topotecan, 349–351 362–365
paclitaxel, 293–297 topoisomerase II inhibitors vesicants, chemotherapy
Taxol (paclitaxel), 293–297 etoposide, 166–169 drug, 393–395
Taxotere (docetaxel), etoposide phosphate, vinblastine (Velban),
139–143 170–173 366–369
temozolomide (Temodar), topotecan (Hycamtin), vinca alkaloids
336–338 349–351 vinblastine, 366–369
teratogenic potential, of toremifene (Fareston), vincristine, 370–374
chemotherapy drugs, 352–354 vinorelbine, 375–378
396 tositumomab (Bexxar), vincristine (Oncovin;
testicular cancer, 467–468 355–358 VCR), 370–374
6-TG (thioguanine), toxicity, of chemotherapy, vinorelbine (Navelbine),
343–345 trastuzumab (Herceptin 375–378
thalidomide (Thalomid), Anti-HER-2-antibody), VP-16 (etoposide), 166–169
339–342 359–361
therapeutic strategies tretinoin (All-trans-retinoic WR2721 (amifostine), 29–31
combination acid; ATRA; Vesanoid),
chemotherapy. See com- 362–365 Xeloda (capecitabine), 65–70
bination chemotherapy, Triethylenethiophosphor-
combination modality. amide (thiotepa), Zanosar (streptozocin),
See chemoradition 346–348 325–327
therapy. Trisenox (arsenic ZD1839 (gefitinib),
single-agent. See single- trioxide), 38–41 198–200
agent regimens, tumor cell growth, kinetics Zevalin (ibritumomab),
thioguanine of, 5–6 214–217
(6-Thioguanine; 6-TG), Zinecard (dexrazoxane),
343–345 VCR (vincristine), 370–374 136–138
thiotepa (Triethylenethio- Velban (vinblastine), Zofran (ondansetron),
phosphoramide; 366–369 521–523
Thioplex), 346–348 Velcade (bortezomib), Zoladex (goserelin),
thymoma, 468–469 59–61 209–210

542 Index